Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03865407 · ClinicalTrials.gov registry record · Phase 2
Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03865407 is a Phase 2 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 17 participants.
The verdict
NCT03865407, a Phase 2 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
Aim 1. To determine the effect of Allopurinol treatment on renal function (glomerular filtration rate, GFR) in pediatric chronic kidney disease (CKD) patients with high uric acid levels (hyperuricemia). Aim 2. Establish whether Allopurinol treatment reduces Nlrp3 inflammasome and renal injury biomarkers.
Interventions
- DRUG Allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-03-10 |
| Est. Completion | 2020-10-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03865407
The ClinicalTrials.gov registry entry for NCT03865407 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allopurinol is the first listed.
NCT03865407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03865407 about?
NCT03865407 is a clinical study titled "Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease". Aim 1. To determine the effect of Allopurinol treatment on renal function (glomerular filtration rate, GFR) in pediatric chronic kidney disease (CKD) patients with high uric acid levels (hyperuricemia). Aim 2. Establish whether Allopurinol treatment reduces Nlrp3 inflammasome and renal injury bioma...
What is the current status of trial NCT03865407?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2019-03-10. Estimated completion is 2020-10-07.
What interventions are being tested in trial NCT03865407?
The interventions under investigation include: Allopurinol (DRUG).
Who is sponsoring clinical trial NCT03865407?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.